

Competitor Analysis: Cancer Vaccines

<https://marketpublishers.com/r/CD6671E2188EN.html>

Date: March 2014

Pages: 179

Price: US\$ 1,112.00 (Single User License)

ID: CD6671E2188EN

Abstracts

The present Competitive Intelligence report about **Cancer Vaccines** provides a competitor evaluation in the field of novel prophylactic and therapeutic vaccines to fight cancer as of March 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Projects are listed according to their main antigenic constituents: peptides, recombinant proteins, idiotype antibody, DNA (plasmid, expression vector), RNA, virus-like particles (VLP), dendritic cells, tumor cells (tumor cell lines), microorganism-based and others.

Of the 140 clinical stage cancer vaccines, three were approved and are commercialized in the major pharmaceutical markets with combined 2013 sales of US\$ 2,385 mln. Peptides and proteins make out 43% of clinical stage cancer vaccines, followed by dendritic cell and tumor cell (line)-based cancer vaccines with each contributing 15% to the clinical cancer vaccine pipeline. DNA- and RNA-based cancer vaccines made out 17% of the clinical portfolio.

The report includes a compilation of currently active projects in research and development for prophylaxis and therapy of cancer. In addition, the report lists company-specific R&D pipelines of cancer vaccines. Competitor projects are listed in a tabular format providing information on:

Drug Codes,

Target / Mechanism of Action,

Class of Compound,

Company,

Product Category,

Indication,

R&D Stage and

additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced."

Contents

1. CANCER VACCINES BY MAIN COMPOSITION

Peptide-based Cancer Vaccines
Protein-based Cancer Vaccines
Idiotypic Antibody-based Cancer Vaccines
DNA-based Cancer Vaccines: naked and virally vectored
RNA-based Cancer Vaccines
Virus-Like Particle (VLP)-based Cancer Vaccines
Dendritic Cell-based Cancer Vaccines
Tumor Cell and Tumor Cell Line – based Cancer Vaccines
Microorganism-based Cancer Vaccines
Other and Not Defined Cancer Vaccines

2. CORPORATE CANCER VACCINES R&D PIPELINES

I would like to order

Product name: Competitor Analysis: Cancer Vaccines

Product link: <https://marketpublishers.com/r/CD6671E2188EN.html>

Price: US\$ 1,112.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CD6671E2188EN.html>